Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) saw strong trading volume on Monday . 68,240 shares traded hands during trading, a decline of 6% from the previous session's volume of 72,456 shares.The stock last traded at $9.71 and had previously closed at $10.32.
Analyst Ratings Changes
Separately, Noble Financial assumed coverage on Gyre Therapeutics in a research report on Tuesday. They set an "outperform" rating for the company.
Check Out Our Latest Report on Gyre Therapeutics
Gyre Therapeutics Trading Up 3.2 %
The firm has a 50-day simple moving average of $11.24 and a 200 day simple moving average of $12.32.
Insider Transactions at Gyre Therapeutics
In other news, President Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares of the company's stock, valued at $37,191,530.90. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 36,054 shares of company stock valued at $406,537 in the last quarter. 19.52% of the stock is owned by insiders.
Hedge Funds Weigh In On Gyre Therapeutics
Large investors have recently modified their holdings of the stock. FMR LLC purchased a new position in shares of Gyre Therapeutics in the 3rd quarter worth about $47,000. Wells Fargo & Company MN raised its position in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock worth $49,000 after purchasing an additional 913 shares during the last quarter. Bank of America Corp DE increased its holdings in Gyre Therapeutics by 40.4% in the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock worth $84,000 after buying an additional 1,996 shares in the last quarter. Barclays PLC increased its holdings in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after buying an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company's stock worth $168,000 after buying an additional 1,389 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company's stock.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
